Recent Activity

Loading...

AMLX

Amylyx Pharmaceuticals, Inc. · NASDAQ

Performance

-3.17%

1W

-8.96%

1M

-88.48%

3M

-84.91%

6M

-87.57%

YTD

-93.41%

1Y

Profile

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Investment Analysis Report: AMLX

Overview

In this investment analysis report, we will delve into a comprehensive analysis of AMLX, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...

See more ...

Technical Analysis of AMLX 2024-05-10

Overview:

In analyzing the technical indicators for AMLX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

  • Moving Averages (MA): The 5-day Moving Average (MA) has been declining steadily, indi...
See more ...

Recent News & Updates